Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Internal Medicine

Infectious Diseases

Virology

Virus

Show all topics

DOI

10.1016/s0140-6736(12)61853-4